Anti-EGFRvIII-CAR

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-EGFRvIII-CAR

Drug Alias NameEFGRvIII CARAnti-EGFRvIII-CAREGFRvIII CAR

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector

Mechanisms of ActionT lymphocyte replacementsAnti-EGFRvIII

TargetsEpidermal growth factor receptor variant III

Therapy Area/IndicationsBrain NeoplasmsGliosarcomaGlioblastoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesKite Pharma National Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesKite Pharma National Cancer Institute

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsBrain NeoplasmsGliosarcomaGlioma

Other Information

ATC CodeN/A